12:45 PM
 | 
Jun 07, 2018
 |  BC Innovations  |  Emerging Company Profile

Radio fusion

How Fusions’ Ac-225 linker improves radiopharmaceutical safety for cancer

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225.

While the newco remains tight-lipped about the linker’s design, SVP of Business Development and U.S. Operations Marc Schwabish told BioCentury the company has shown its linkers improve the safety of IV antibody-radioisotope conjugates over those based on a standard linker -- one widely used in radiopharmaceuticals -- by increasing the excretion of unbound radioactive particles in mice. “With our linker, we have almost four times more of the unbound radioactivity excreted from the body.”

In addition to increasing the total amount of radioactivity excreted by the body, he said, Fusion’s linkers “can also push more radioactivity via...

Read the full 580 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >